Because BRCA1/2 carriers already possess an underlying risk for ovarian cancer, use of clomiphene citrate in these patients must be carefully monitored and considered on a patient-by-patient basis (FDA, 2012; Reigstad et al., 2017). The gene discussed is BRCA1; the disease is ovarian cancer.